New and emerging immune-targeted drugs for the treatment of multiple sclerosis

Authors

  • Alan M. Palmer

    Corresponding author
    1. MS Therapeutics Ltd, Crowthorne, Berks, UK
    2. Department of Research and Enterprise Development, University of Bristol, Bristol, UK
    • Correspondence

      Professor Alan Palmer, MS Therapeutics Ltd., Beechey House, 87 Church Street, Crowthorne, Berks RG45 7AW, UK.

      Tel.: +44 077 5705 8054

      E-mail: alan.palmer@mstherapeutics.com

    Search for more papers by this author

Abstract

Multiple sclerosis (MS) is a neurodegenerative disease with a major inflammatory component that constitutes the most common progressive and disabling neurological condition in young adults. Injectable immunomodulatory medicines such as interferon drugs and glatiramer acetate have dominated the MS market for over the past two decades but this situation is set to change. This is because of: (i) patent expirations, (ii) the introduction of natalizumab, which targets the interaction between leukocytes and the blood–CNS barrier, (iii) the launch of three oral immunomodulatory drugs (fingolimod, dimethyl fumarate and teriflunomide), with another (laquinimod) under regulatory review and (iv) a number of immunomodulatory monoclonal antibodies (alemtuzumab, daclizumab and ocrelizumab) about to enter the market. Current and emerging medicines are reviewed and their impact on people with MS considered.

Ancillary